News and Media

Press Release

iCo Therapeutics Announces Strategic Advisory Team

November 30, 2005

VANCOUVER, Canada—iCo Therapeutics Inc. announced today the company’s newly-formed Strategic Advisory Team. Team members Dr. Julia Levy, Dr. George Lasezkay and Richard Glickman will assist iCo’s management team and Board chart the company’s strategy for growth and development.

“We are extremely pleased to have such an esteemed group of science and business advisors helping us to achieve our goals,” said Andrew Rae, iCo President and CEO.

Dr. Julia Levy, co-founder and former President and CEO of QLT Inc., is currently Executive Chairman of the Scientific Advisory Board at QLT. Under Dr. Levy’s stewardship QLT rose to become one the leading biotech companies worldwide with the launch of Visudyne in 2000 to treat age-related macular degeneration. A former microbiology professor at the University of British Columbia and a Fellow of the Royal Society of Canada, Dr. Levy was selected Female Entrepreneur of the Year for International Business in 1998 by Canadian Business magazine, and appointed to the Order of Canada in 2001. She received a B.A. (Hon.) from the University of British Columbia and a Ph.D. in experimental pathology from the University of London.

Dr. Lasezkay is a principal in Turning Point Consultants, LLC, a consultancy group that advises life science companies on strategy and business development, and he is a former Corporate Vice President of Corporate Development at Allergan, a global ophthalmology pharmaceutical company. He also has extensive experience in hospital pharmacy practice, clinical pharmacokinetics consultation, drug research and pharmacy education. Dr. Lasezkay earned B.S. Pharmacy and Doctor of Pharmacy degrees from the State University of New York at Buffalo and a J.D. degree from the University of Southern California Law Center. He currently serves as a director of Valentis Inc., Collagenex Pharmaceuticals, Acuity Pharmaceuticals, Sucampo Pharmaceuticals, and Novagali Pharma, SA.

Mr. Richard Glickman is co-founder, CEO and Chairman of Aspreva Pharmaceuticals Corporation and has a successful track record raising capital for pharmaceutical and biopharmaceutical companies, including Stressgen Biotechnologies Corp., where he served as CEO. Mr. Glickman was the founder and director of Ontario Molecular Diagnostics, a former director of the Canadian Genetic Diseases Network and a co-founder of Probtec Corp. where, as vice-president he established and introduced Canada’s first licensed DNA-based forensic and paternity testing service. Mr. Glickman has received both Canada’s and British Columbia’s Top 40 under 40 Awards for entrepreneurs and was the Ernst & Young 2004 Entrepreneur of the Year recipient for Life Sciences.

About iCo Therapeutics, Inc.

iCo Therapeutics Inc. is an emerging, Vancouver-based biotechnology company focused on developing pre-existing drugs for a range of new conditions affecting isolated biological environments – areas such as the eye, spinal cord, or joints – where locally-administered application of these therapies would have minimal systemic distribution and fewer safety issues.

For more information, visit the company website at:

Business Development Contact:
Dr. John Clement, CTO

Finance/Investor Contact:
Mr. John Meekison, CFO